Advertisement

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Published:October 11, 2022DOI:https://doi.org/10.1016/j.jtho.2022.09.225

      Abstract

      Introduction

      Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2, encoded by NFE2L2, and its upstream regulator, KEAP1, control key aspects of redox balance and are frequently mutated in NSCLCs.

      Methods

      Here, we describe the specific potent activity of TAK-228, a TORC1/2 inhibitor, in NSCLC models harboring NRF2-activating alterations and results of a phase 2 clinical trial of TAK-228 in patients with advanced NSCLC harboring NRF2-activating alterations including three cohorts (NFE2L2-mutated LUSC, KEAP1-mutated LUSC, KRAS/NFE2L2- or KEAP1-mutated NSCLC).

      Results

      TAK-228 was most efficacious in a LUSC cohort with NFE2L2 alterations; the overall response rate was 25% and median progression-free survival was 8.9 months. Additional data suggest that concurrent inhibition of glutaminase with the glutaminase inhibitor CB-839 might overcome metabolic resistance to therapy in these patients.

      Conclusions

      TAK-228 has single-agent activity in patients with NRF2-activated LUSC. This study reframes oncogenic alterations as biologically relevant based on their downstream effects on metabolism. This trial represents, to the best of our knowledge, the first successful attempt at metabolically targeting NSCLC and identifies a promising targeted therapy for patients with LUSC, who are bereft of genotype-directed therapies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.L.
        • Torre L.A.
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Paz-Ares L.
        • Luft A.
        • Vicente D.
        • et al.
        Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer.
        N Engl J Med. 2018; 379: 2040-2051
        • Paik P.K.
        • Shen R.
        • Berger M.F.
        • et al.
        A phase 1b open label multicentre study of AZD4547 in patients with advanced squamous cell lung cancers.
        Clin Cancer Res. 2017; 23 (5366–4373)
        • Nogova L.
        • Sequist L.V.
        • Perez Garcia J.M.
        • et al.
        Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study.
        J Clin Oncol. 2017; 35: 157-165
        • Wade J.L.
        • Langer C.J.
        • Redman M.
        • et al.
        A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.
        J Clin Oncol. 2017; 35: 9054
        • Edelman M.J.
        • Redman M.W.
        • Albain K.S.
        • et al.
        A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.
        J Clin Oncol. 2017; 35: 9056
        • Paik P.K.
        • Shen R.
        • Won H.
        • et al.
        Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases.
        Cancer Discov. 2015; 5: 610-621
        • Taguchi K.
        • Motohashi H.
        • Yamamoto M.
        Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
        Genes Cells. 2011; 16: 123-140
        • Shibata T.
        • Saito S.
        • Kokubu A.
        • Suzuki T.
        • Yamamoto M.
        • Hirohashi S.
        Global downstream pathway analysis reveals a dependence of oncogenic NF-E2–related factor 2 mutation on the mTOR growth signaling pathway.
        Cancer Res. 2010; 70: 9095-9105
        • Mahida J.P.
        • Antczak C.
        • Decarlo D.
        • et al.
        A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma.
        PLoS One. 2013; 8e59156
        • Shum D.
        • Radu C.
        • Kim E.
        • et al.
        A high density assay format for the detection of novel cytotoxic agents in large chemical libraries.
        J Enzyme Inhib Med Chem. 2008; 23: 931-945
        • Slotkin E.K.
        • Patwardhan P.P.
        • Vasudeva S.D.
        • de Stanchina E.
        • Tap W.D.
        • Schwartz G.K.
        MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
        Mol Cancer Ther. 2015; 14: 395-406
        • Gökmen-Polar Y.
        • Liu Y.
        • Toroni R.A.
        • et al.
        Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
        Breast Cancer Res Treat. 2012; 136: 673-682
        • Jiang H.
        • Zeng Z.
        Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
        Biochem Biophys Res Commun. 2015; 468: 255-261
        • Nyfeler B.
        • Chen Y.
        • Li X.
        • et al.
        RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth.
        PLoS One. 2012; 7e48548
        • Xu C.X.
        • Li Y.
        • Yue P.
        • et al.
        The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
        PLoS One. 2011; 6e20899
        • Zheng B.
        • Mao J.H.
        • Qian L.
        • et al.
        Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
        Cancer Lett. 2015; 357: 468-475
        • Cheng D.T.
        • Mitchell T.N.
        • Zehir A.
        • et al.
        Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.
        J Mol Diagn. 2015; 17: 251-264
        • Ghobrial I.M.
        • Siegel D.S.
        • Vij R.
        • et al.
        TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
        Am J Hematol. 2016; 91: 400-405
        • Moore K.N.
        • Bauer T.M.
        • Falchook G.S.
        • et al.
        Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
        ESMO Open. 2018; 3e000291
        • Dunphy M.P.S.
        • Harding J.J.
        • Venneti S.
        • et al.
        In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of 18F-(2S,4R)-4-fluoroglutamine.
        Radiology. 2018; 287: 667-675
        • Voss M.
        • Gordon M.S.
        • Mita M.
        • et al.
        354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: expansion phase in patients with renal, endometrial, or bladder cancer.
        Eur J Cancer. 2015; 51: S72
        • Romero R.
        • Sayin V.I.
        • Davidson S.M.
        • et al.
        Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
        Nat Med. 2017; 23: 1362-1368
        • Momcilovic M.
        • Bailey S.T.
        • Lee J.T.
        • et al.
        The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma.
        Cancer Cell. 2018; 33: 905-921.e5
        • Satpathy S.
        • Krug K.
        • Jean Beltran P.M.
        • et al.
        A proteogenomic portrait of lung squamous cell carcinoma.
        Cell. 2021; 184: 4348-4371.e40
        • Goodwin J.
        • Neugent M.L.
        • Lee S.Y.
        • et al.
        The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
        Nat Commun. 2017; 815503
        • Bendell J.C.
        • Varghese A.M.
        • Hyman D.M.
        • et al.
        A first-in-human Phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer.
        Clin Cancer Res. 2018; 24: 3253-3262
        • Adjei A.A.
        • Bennouna J.
        • Leighl N.B.
        • et al.
        Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): results from the phase Ib/II BASALT-2 and BASALT-3 studies.
        J Clin Oncol. 2016; 34 (e20522–e20522)
        • Haura E.B.
        • Hicks J.K.
        • Boyle T.A.
        Erdafitinib overcomes FGFR3-TACC3-mediated resistance to osimertinib.
        J Thorac Oncol. 2020; 15: e154-e156
        • Loriot Y.
        • Necchi A.
        • Park S.H.
        • et al.
        Erdafitinib in locally advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2019; 381: 338-348